WO2003002743A1 - Human cervical cancer 7 proto-oncogene and protein encoded therein - Google Patents
Human cervical cancer 7 proto-oncogene and protein encoded therein Download PDFInfo
- Publication number
- WO2003002743A1 WO2003002743A1 PCT/KR2002/001226 KR0201226W WO03002743A1 WO 2003002743 A1 WO2003002743 A1 WO 2003002743A1 KR 0201226 W KR0201226 W KR 0201226W WO 03002743 A1 WO03002743 A1 WO 03002743A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oncogene
- proto
- fragment
- hcc
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a novel proto-oncogene and protein encoded therein, and more particularly, to a human cervical cancer proto- oncogene 7 (hereinafter "HCC-7 proto-oncogene”) and a protein derived therefrom, which can be used in diagnosis of various cancers.
- HCC-7 proto-oncogene human cervical cancer proto- oncogene 7
- protein derived therefrom which can be used in diagnosis of various cancers.
- DD rnRNA differential display
- tumorigenesis is caused by various genetic changes such as the loss of chromosomal heterozygosity, activation of oncogenes and inactivation of tumor suppressor genes, e.g., p53 gene (Bishop, J. M., Cell, 64: 235-248(1991); and Hunter, T., Cell, 64: 249-270(1991)). Further, it has been reported that 10 to 30 % of human cancer arises from the activation of oncogene through amplification of proto-oncogenes.
- the present inventor has endeavored to unravel the mechanism involved in the tumorigenesis of cervical cancer; and, has unexpectedly found that a novel proto-oncogene, HCC-7 (Human Cervical Cancer 7), is specifically over- expressed in cancer cells.
- HCC-7 Human Cervical Cancer 7
- This proto-oncogene can be advantageously used in diagnosis, prevention and treatment of various cancers, e.g., leukemia, lymphoma, colon, lung, skin, and uterine cervix cancers.
- the primary object of the present invention is to provide a novel proto-oncogene and a fragment thereof.
- a protein encoded in said proto-oncogene or a fragment thereof A kit for diagnosis of cancer containing said proto-oncogene or a fragment thereof;
- a kit for diagnosis of cancer containing said protein or a fragment thereof;
- An anti-sense gene having a base sequence complementary to that of said proto-oncogene or a fragment thereof;
- a process for treating or preventing cancer by using said anti-sense gene there is provided a novel proto-oncogene having the nucleotide sequence of SEQ ID NO: 1 or a fragment thereof.
- a recombinant vector containing said proto-oncogene or a fragment thereof and a microorganism transformed with said vector.
- a protein having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof derived from said proto-oncogene or a fragment thereof.
- Fig. 1 the result of DDRT-PCR, which verifies the manifestation of CG232 in CUMC-6 cancer cells, normal and tumor tissues of cervix, and metastatic tissues of lymph nodes.
- Fig. 2A the result of Northern blot analysis, which verifies the manifestation of HCC-7 proto-oncogene of the present invention in cervical cancer tissues.
- Fig. 2B the result obtained with the same sample of Fig. 2A hybridized with ⁇ -actin.
- Fig. 3A the result of Northern blot analysis for HCC-7 proto-oncogene expressed in normal human 12-lane multiple tissues.
- Fig. 3B the results obtained with the same sample of Fig. 3 A hybridized with ⁇ -actin.
- Fig. 4A the result of Northern blot analysis for HCC-7 proto-oncogene expressed in human cancer cell lines.
- Fig. 4B the result obtained with the same sample of Fig. 4A hybridized with ⁇ -actin.
- Fig. 5 the sodium dodecyl sulfate (SDS)-PAGE results showing protein expression patterns and protein size before and after the IPTG induction of E. coli transformed with HCC-7 proto-oncogene.
- the novel proto-oncogene of the present invention i.e., human cervical cancer 7 (HCC-7), consists of 1892 base pairs and has the DNA sequence of SEQ ID NO: 1.
- SEQ TD NO: 1 the full open reading frame corresponding to base Nos. 73 to 1743 (1741-1743: termination codon) is a protein encoding region and the predicted amino acid sequence derived therefrom is shown in SEQ LD NO: 2 which consists of 556 amino acids (hereinafter "HCC-7 protein").
- the present invention also includes, in its scope, a polynucleotide having substantially the same base sequence as the inventive proto-oncogene, and a fragment thereof.
- substantially the same polynucleotide refers to a polynucleotide whose base sequence shows 80 % or more, preferably 90 % or more, most preferably 95 % or more homology to the proto-oncogene of the present invention.
- the protein expressed from the proto-oncogene of the present invention consists of 556 amino acids and has the amino acid sequence of SEQ ID NO: 2.
- the molecular weight of this protein is about 63 kDa.
- various substitution, addition and/or deletion of the amino acid residues of protein may be performed without adversely affecting the protein's function.
- a portion of the protein may be used when a specific purpose is to be fulfilled.
- These modified amino acid sequence and fragments thereof are also included in the scope of the present invention. Therefore, the present invention includes, in its scope, a polypeptide having substantially the same amino acid sequence as the protein derived from the oncogene of the present invention and a fragment thereof.
- substantially the same polypeptide refers to a polypeptide whose amino acid sequence shows 80 % or more, preferably 90 % or more, most preferably 95 % or more homology to the amino acid sequence of SEQ ID NO: 2.
- the proto-oncogene HCC-7, or the protein of the present invention can be obtained from human cancer tissues or synthesized using a conventional DNA or peptide synthesis method. Further, the gene thus prepared may be inserted to a conventional vector to obtain an expression vector, which may, in turn, be introduced into a suitable host, e.g., a microorganism such as an E. coli or yeast.
- a suitable host e.g., a microorganism such as an E. coli or yeast.
- E. coli DH5 ⁇ was transfected with an expression vector comprising proto-oncogene HCC-7, and E. coli DH5 ⁇ HCC-7/pCEV-LAC thus obtained was deposited with the Korean Collection for Type Cultures (KCTC)
- expression-control sequences e.g., promoter, and terminator, etc., self-replication sequence and secretion signal, are suitably selected depending on the host cell used.
- the novel proto-oncogene HCC-7 is not manifested in normal uterus tissues but it is manifested in uterine and cervical cancer tissues; therefore, HCC-7 is believed to be a type of carcinogen.
- the over expression of the proto-oncogene HCC-7 of the present invention is also observed in cancers as leukemia, lymphoma, colon, lung and skin cancers. Therefore, the proto- oncogene of the present invention is believed to be a factor common to all forms of various cancer and it can be advantageously used in the diagnosis of cancers and the production of a transformed animal as well as in an anti-sense gene therapy.
- a diagnostic method that can be performed using the proto-oncogene of the present invention may comprise, for example, the steps of hybridizing nucleic acids separated from the body fluid of a subject with a probe containing the proto-oncogene of the present invention or a fragment thereof, and determining whether the subject has the proto-oncogene by using a conventional detection method known in the art.
- the presence of the proto-oncogene HCC-7 may be easily detected by labeling the probe with a radioisotope or an enzyme. Therefore, a cancer diagnostic kit containing the proto-oncogene of the present invention or a fragment thereof is also included in the scope of the present invention.
- a transformed animal produced by introducing the proto-oncogene of the present invention into a mammal, e.g., mice, is also included in the scope of the present invention.
- the transformed animal can be advantageously used in screening for carcinogens or anticancer agents such as chemotherapeutic drugs.
- the present invention is also effective in gene therapy, and it also provides an anti-sense gene comprising an mRNA complimentary base sequence that is induced by the novel proto-oncogene HCC-7 or its fragment.
- the present invention also provides an anti-sense gene, which is useful in a gene therapy.
- anti-sense gene means a polynucleotide comprising a base sequence which is fully or partially complementary to the sequence of the mRNA which is transcribed from the proto-oncogene HCC-7 having the base sequence of SEQ ID NO: 1 or a fragment thereof, said nucleotide being capable of preventing the expression of the open reading frame (ORF) of the proto-oncogene by way of attaching itself to the protein-binding site of mRNA.
- ORF open reading frame
- the present invention also includes within its scope a process for treating or preventing cancer in a subject by way of administering a therapeutically effective amount of the inventive anti-sense gene thereto.
- the anti-sense gene of the present invention is administered to a subject in a conventional manner to prevent the expression of the proto-oncogene.
- the anti-sense oligodeoxynucleotide (ODN) is mixed with a hydrophobicized poly-L-lysine derivative by electrostatic interaction in accordance with the method disclosed by Kim, J.S. et al. (J. Controlled Release, 53: 175-182(1998)) and the resulting mixed anti-sense ODN is administered intravenously to a subject.
- the present invention also includes within its scope an anti-cancer composition comprising the HCC-7 anti-sense gene of the present invention as an active ingredient, in association with pharmaceutically acceptable carriers, excipients or other additives, if necessary.
- the pharmaceutical composition of the present invention is preferably formulated for administration by injection.
- the amount of the HCC-7 anti-sense gene actually administered should be determined in light of various relevant factors including the condition to be treated, the chosen route of administration, the age and weight of the individual patient, and the severity of the patient's symptoms.
- the protein expressed from the inventive proto-oncogene HCC-7 may be used in producing an antibody useful as a diagnostic tool.
- the antibody of the present invention may be prepared in the form of a monoclonal or polyclonal antibody in accordance with any of the methods well known in the art by using a protein having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof.
- Cancer diagnosis may be carried out using any of the methods known in the art, e.g., enzyme linked immunosorbentassay (ELISA), radioimmunoassay (RIA), sandwich assay, immunohistochemical staining, western blot or immunoassay blot on polyacrylic gel, to assess whether the protein is expressed in the body fluid of the subject. Therefore, a cancer diagnostic kit containing the protein having the amino acid sequence of SEQ ID NO: 2 or a fragment thereof is also included in the scope of the present invention.
- a continuously viable cancer cell line may be established by using the proto-oncogene of the present invention, and such a cell line may be obtained, for example, from tumor tissues formed on the back of a nude mouse by injecting fibroblast cells transformed with the proto-oncogene of the present invention.
- the cell lines thus prepared may be advantageously used in searching for anti-cancer agents.
- Example 1 Tumor cell culture and isolation of the total RNA
- the cells obtained from the above-mentioned tissues and CUMC-6 cell line were cultured in Waymouth's MB 752/1 culture solution (Gibco, USA) containing 2 mM glutamine, 100 IU/m- ⁇ penicillin, 100 ⁇ gM streptomycin, and 10 % bovine fetal serum (Gibco, USA).
- the cells that show 95% viability while being dyed with trypan blue were used in this example (Freshney, "Culture of Animal Cells: A Manual of Basic Technique" 2 nd Ed., A.R. Liss New York, 1987).
- Step 2 Isolation of RNA and mRNA Differential Display
- RNAs were extracted from the tissue specimens and cells from Step 1 using a commercial system (RNeasy total RNA kit, Qiagen Inc., Germany), and DNA contaminants were removed therefrom using Message clean kit (GenHunter Corp., Brookline, MA).
- Example 2 Differential Display Reverse Transcription, DDRT-PC Differential display was conducted according to Liang and Pardee's RT- PCR (Science, 257: 967-971 (1992) with minor modifications as follows.
- each of the total RNAs obtained in Step 1 of Example 1 was subjected to reverse transcription using H-T11C primer of SEQ ID NO: 3 as an anchored oligo-dT primer (RNAimage kit, GenHunter, cor., MA, USA), followed by polymerase chain reaction (PCR) using the same anchored primer and the primer of SEQ ID NO: 4 (H-AP23 primer among RNAimage primer sets 1-4, H-AP 1-32) in the presence of 0.5 mM [ ⁇ - 35 S] abeled dATP (1200 Ci/mmol).
- the PCR thermal cycle was repeated 40 times, each cycle being composed of: 95 ° C for 40 sec, 40 ° C for 2 min.
- T4 DNA ligase (3 Stamms ⁇ l ⁇ l; T4 DNA ligase, Promega) were added into a
- Step 2 TA Cloning Transformation
- E. coli JM109 was cultured in 10 ml LB broth (Bacto-Trip 10 g, Bacto- yeast extract 5 g, NaCl 5 g) until its optical density reached approximately 0.3 to
- the culture mixture was kept in ice for about 10 minutes, then centrifuged at 4°C for 10 minutes at 4000 rpm in order to isolate bacterial cells.
- the bacterial cells thus obtained were exposed in 10 ml of ice-cold 0.1 M CaCl 2 for 30 minutes to 1 hour to produce competent cells.
- the resultant mixture was centrifuged at 4 ° C for 10 minutes at 4000 rpm.
- the cells are collected then suspended in 2 ml of ice-cold O.lM CaC ⁇ .
- coli JM109/CG232 was selected and cultured on 10 ml of terrific broth (TDW 900 ml, Bacto-Trip 12 g, Bactor-yeast extract 24 g, glycerol 4 ml, 0.17 M KH 2 P0 4 , 0.72 M K 2 HP0 4 100 ml).
- CG232 plasmid DNA was separated from the transformed E. coli.
- the separated plasmid DNA was treated with EcoRI restriction enzyme, and subjected to 2% gel electrophoresis to confirm the insertion of CG232 sequence in the plasmid.
- the CG232 PCR product obtained in Example 2 was amplified using a known method, and cloned.
- the sequence of the amplified CG232 PCR fragment analyzed using the Sequenase version 2.0 DNA sequencing kit (United States Biochemical, Cleveland, OH, USA) according to the dideoxy chain termination method corresponded to nucleotide numbers 1538 to 1853 of SEQ ID NO:l and this DNA fragment was designated "CG232".
- the cDNA fragment of 316 bp obtained above was subjected to DDRT-PCR and then verified through electrophoresis. As illustrated in Figure 1, the cDNA fragment (CG232) was expressed in metastasis lymph node tissues and CUMC-6 cells but not in normal tissues.
- a bacteriophage ⁇ gtll human lung embryonic fibroblast cDNA library (Miki, T. et. al., Gene, 83:137-146, 1989) was screened by plaque hybridization with P-labeled CG232 cDNA probe. From the human lung embryonic fibroblast cDNA library, a full length HCC-7 cDNA clone in vector pCEV-LAC was obtained. This vector was registered at GenBank, USA on May 5, 2001 (GenBank No.: AF378118; Open to public: July 1, 2002).
- HCC-7 has the 1892 bp sequence of SEQ ED NO: 1 and it is hypothesized that, in the base sequence of SEQ ID NO: 1, the entire open reading frame of the HCC-7 proto-oncogene is believed to correspond to the nucleotide number 73 to 1743 which encodes the protein of SEQ ID NO: 2.
- the HCC-7 clone inserted in ⁇ pCEV vector was cleaved with Not I to obtain an ampicillin resistant pCEV-LAC phagemid vector' (Miki, T. et. al., Gene, 83:137-146, 1989).
- the pCEV-LAC vector containing the HCC-7 gene was ligated using T4 DNA ligase to produce HCC-7 plasmid DNA, and then E. coli DH5 ⁇ was transformed with the ligated clones.
- the recombinant E. coli. DH5 ⁇ /HCC-7/ ⁇ CEV-LAC thus obtained was deposited with Korean Collection for Type Cultures, KCTC (Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB), #52 Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea) on June 2, 2001 under the accession number of KCTC 1027BP in accordance with the terms of Budapest Treaty on the International Recognition of the Deposit of Microorganism for the Purpose of Patent Procedure.
- Korean Collection for Type Cultures KCTC (Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB), #52 Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea) on June 2, 2001 under the accession number of KCTC 1027BP in accordance with the terms of Budapest Treaty on the International Recognition of the Deposit of Microorganism for the Purpose of Patent Procedure.
- RNAs were prepared from normal exocervical tissue, primary cervical cancer tissue; and human cervical cancer cell lines CaSki (ATCC CRL 1550) and CUMC-6, respectively, by repeating the procedure of Example 1. 20 ⁇ g each of the denatured total RNAs was electrophoresed through 1% formaldehyde agarose gel and transferred to a nylon membrane (Boehringer- Mannheim, Germany). The blots were hybridized overnight at 42 °C with 32 P- labeled random-primed HCC-7 cDNA probe which was prepared using a Rediprime II random prime labeling system (Amersham, England). The northern blot analysis was repeated twice and the result was quantified by densitometry. The blots were hybridized with a ⁇ -actin probe to confirm mRNA integrity.
- Fig. 2A shows the Northern blot analysis results obtained for normal cervical tissues, primary cervical cancer tissues and cervical cancer cell lines CUMC-6 and CaSki using the HCC-7 cDNA probe; and Fig. 2B, the same blots, hybridized with a ⁇ -actin probe.
- the expression level of HCC-7 gene was elevated in the cervical cancer tissues and the cervical cancer cell lines but nearly absent in all normal cervical tissues.
- Fig. 3A shows the Northern blot analysis results obtained for normal human tissues of brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood leukocyte (Clontech), using HCC-7 cDNA probe; and Fig. 3B, the same blot, hybridized with a ⁇ - actin probe.
- HCC-7 mRNA (-3.1 kb) is faint or nearly absent in normal tissues.
- Fig. 4A shows the Northern blot analysis results obtained for HCC-7 proto-oncogene expressed in human cancer cell lines, HL-60, HeLa, K-562, MOLT-4, Raji cell, SW480, A549, and G361 (Clontech), and Fig. 4B, the blots hybridized with a ⁇ -actin probe to detect the existence of mRNA.
- Fig. 4A shows the Northern blot analysis results obtained for HCC-7 proto-oncogene expressed in human cancer cell lines, HL-60, HeLa, K-562, MOLT-4, Raji cell, SW480, A549, and G361 (Clontech)
- Fig. 4B the blots hybridized with a ⁇ -actin probe to detect the existence of mRNA.
- HCC-7 is overexpressed in SW480 colon cancer cell, lung cancer cell line A549, and skin cancer cell line G361, and transcribed especially at a high level in promyelocytic leukemia HL-60, HeLa uterine cancer cell line, chronic myelogenous leukemia K-562, lymphoblastic leukemia MOLT-4 and Burkitt's lymphoma Raji.
- Example 8 Determination of the size of the protein expressed after the transfection of E. coli with HCC-7 proto-oncogene
- HCC-7 proto-oncogene of SEQ ID NO: 1 was inserted into the multiple cloning site of pGEX-4T-3 vector (Amersham Pharmacia) and the resulting pGEX-4T-3/HCC-7 vector was transfected into E. coli BL21 (ATCC 47092). Glutathione-S-transferase (GST) is inserted at the front of the pGEX- 4T-3 vector multiple cloning site.
- Glutathione-S-transferase GST
- the transfected E. coli was incubated using an LB broth medium in a rotary shaking incubator, diluted by 1/100, and incubated for 3 hours. 1 mM isopropyl ⁇ -D-fhiogalacto-pyranoside (IPTG, Sigma) was added thereto to induce the protein synthesis.
- Fig. 5 shows the SDS-PAGE results, which exhibit a protein expression pattern of the E. coli BL21 strain, transfected with ⁇ GEX-4T-3 HCC-7 vector. After the IPTG induction, a significant protein band was observed at about 89 kDa. This 89 kDa fused protein contained of GST protein about 26 kDa and HCC-7 protein of approximately 63 kDa.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0037588A KR100459024B1 (en) | 2001-06-28 | 2001-06-28 | Human protooncogene and protein encoded by same, expression vector containing same, and cell transformed by said vector |
KR2001/37588 | 2001-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003002743A1 true WO2003002743A1 (en) | 2003-01-09 |
Family
ID=19711459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2002/001226 WO2003002743A1 (en) | 2001-06-28 | 2002-06-27 | Human cervical cancer 7 proto-oncogene and protein encoded therein |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100459024B1 (en) |
WO (1) | WO2003002743A1 (en) |
-
2001
- 2001-06-28 KR KR10-2001-0037588A patent/KR100459024B1/en not_active IP Right Cessation
-
2002
- 2002-06-27 WO PCT/KR2002/001226 patent/WO2003002743A1/en not_active Application Discontinuation
Non-Patent Citations (4)
Title |
---|
DATABASE PUBMED [online] accession no. NCBI Database accession no. (M13519) * |
KOTNELUK R.G. ET AL.: "Isolation of cDNA clones coding for the alpha-subunit of human beta-hexosaminidase. Extensive homology between the alpha- and beta-subunits and studies on Tay-Sachs disease", J. BIOL. CHEM., vol. 261, no. 18, 1986, pages 8407 - 8413, XP002980642 * |
MAHURAN D.J.: "Biochemical consequences of mutations causing the GM2 gangliosides", BIOCHIM. BIOPHYS. ACTA, vol. 1455, 1999, pages 105 - 138, XP004276901, DOI: doi:10.1016/S0925-4439(99)00074-5 * |
NEOTE K. ET AL.: "Characterization of the human HEXB gene encoding lysosomal beta-hexosaminidase", GENOMICS, vol. 3, no. 4, 1988, pages 279 - 286, XP024797594, DOI: doi:10.1016/0888-7543(88)90116-4 * |
Also Published As
Publication number | Publication date |
---|---|
KR100459024B1 (en) | 2004-12-03 |
KR20030001804A (en) | 2003-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6905844B2 (en) | Human cervical cancer 2 protooncogene and protein encoded therein | |
KR100367978B1 (en) | Human cervical cancer 1 protooncogene and protein encoded therein | |
US20060234967A1 (en) | Human protooncogene and protein encoded therein | |
JP2008534007A (en) | Human proto-oncogene TRG and protein encoded by the proto-oncogene | |
WO2003002744A1 (en) | Human cervical cancer 2 proto-oncogene and protein encoded therein | |
WO2003002743A1 (en) | Human cervical cancer 7 proto-oncogene and protein encoded therein | |
WO2004003203A1 (en) | Human cervical cancer 5 protooncogene and protein encoded therein | |
KR100503559B1 (en) | Human protooncogene hlc-8 and protein encoded therein | |
CA2592466A1 (en) | Human protooncogene and protein encoded therein | |
KR100503567B1 (en) | Human protooncogene hlc-2 and protein encoded therein | |
WO2004005514A1 (en) | Human protooncogene 6 and protein encoded therein | |
KR100503564B1 (en) | Human protooncogene hcc-9 and protein encoded therein | |
JP2004514447A (en) | Human proto-oncogene and proteins encoded by it | |
KR100453478B1 (en) | Human protooncogene and protein encoded therein | |
KR100454064B1 (en) | Human protooncogene and protein encoded therein | |
KR100503566B1 (en) | Human protooncogene hlc-4 and protein encoded therein | |
KR20020081773A (en) | Human protooncogene and protein encoded therein | |
CA2457066A1 (en) | Human protooncogene kg-20 and protein encoded therein | |
KR20020083777A (en) | Human protooncogene and protein encoded therein | |
WO2003076563A2 (en) | Human protooncogene and protein encoded therein | |
KR20040056162A (en) | Human protooncogene hcc-10 and protein encoded therein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |